According to Eisai, the arrangement covers the development of a combination antiemetic agent (in both oral and intravenous forms) containing netupitant (generic name), a neurokinin-1 (NK1) receptor antagonist, and palonosetron (generic name, brand name: Aloxi), a serotonin-3 (5-HT3) receptor antagonist.
As per the terms of the agreement, Helsinn will be responsible for conducting clinical trials, obtaining regulatory approvals, and holding the new drug application in the US.
If approved, the new products will be co-promoted by Eisai and Helsinn Therapeutics (US). Additionally, Helsinn’s manufacturing affiliate in Ireland, Helsinn Birex Pharmaceuticals, will be responsible for the manufacture and supply of finished products for clinical and commercial use in the US. Eisai will book sales of the products in the US.
Currently, Eisai has North American distribution and marketing rights from Helsinn Healthcare for Aloxi (generic name: palonosetron hydrochloride) injection 0.25mg, an antiemetic agent indicated for the prevention of chemotherapy-induced nausea and vomiting. The expanded relationship with Helsinn will help Eisai strengthen its presence in the area of anti-emesis therapy in the US.